Tuesday September 19th 2017

FDA Approves New Dose of Copaxone To Be Taken Less Frequently

On January 28, the FDA approved a new dose of glatiramer acetate (Copaxone,® Teva Pharmaceuticals Industries, Ltd.) injected under the skin three times per week, at double the standard 20mg/mL dose, for relapsing MS. This long-approved MS disease-modifying therapy is normally taken every day. The approval was based on benefits and safety demonstrated by a company-sponsored, one-year, phase III trial comparing the higher, less-frequent dose of Copaxone with placebo.

See the original article here:  

FDA Approves New Dose of Copaxone To Be Taken Less Frequently

Leave a Comment

More from category

Scientists discover markers for progressive multiple sclerosis
Scientists discover markers for progressive multiple sclerosis

Scientists have uncovered two closely related cytokines -- molecules involved in cell communication and movement -- [Read More]

Study uncovers markers for severe form of multiple sclerosis
Study uncovers markers for severe form of multiple sclerosis

Scientists have uncovered two molecules involved in cell communication and movement that may explain why some people [Read More]

Costly drugs to weigh on U.S. employers’ expenses in 2018: survey
Costly drugs to weigh on U.S. employers’ expenses in 2018: survey

(Reuters) - U.S. employers are bracing for higher health care expenses in 2018 as spending on new drugs to treat [Read More]

TG Therapeutics commences enrolment for Phase III multiple sclerosis trials
TG Therapeutics commences enrolment for Phase III multiple sclerosis trials

US-based biopharmaceutical firm TG Therapeutics has commenced enrolment for the Phase III ULTIMATE clinical programme [Read More]

Therapy could offer new hope for MS patients
Therapy could offer new hope for MS patients

Multiple sclerosis sufferer Roy Palmer and his wife Helen (pictured) are desperate for him to be able to walk again. [Read More]